Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab Maintenance in Crohn's Disease (CLASSIC II)
NCT00055497Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Aug 2002
- Primary completion
- Jan 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in Crohn's disease (4 arms), sponsored by Abbott Laboratories. Primary endpoint: Clinical Remission (CDAI < 150) at 56 weeks. Started Aug 2002; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00055497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055497.